EDX Medical Group PLC EDX Medical-Thermo Fisher Scientific collaboration (0562U)
November 21 2023 - 1:00AM
UK Regulatory
TIDMEDX
RNS Number : 0562U
EDX Medical Group PLC
21 November 2023
This announcement contains inside information as stipulated
under the UK version of the Market Abuse Regulation No 596/2014
which is part of English law by virtue of the European (Withdrawal)
Act 2018, as amended. On publication of this announcement via a
regulatory information service, this information is considered to
be in the public domain.
EDX Medical announces collaboration with Thermo Fisher
Scientific to develop innovative cancer tests for global healthcare
markets
EDX Medical Group plc -- EDX
21 November 2023
CAMBRIDGE, UK: EDX Medical Group ("EDX Medical"), a developer of
innovative digital diagnostic products and services for
personalised treatment of cancer, heart disease and infectious
diseases, today announced it has entered into a collaborative
agreement with Thermo Fisher Scientific EMEA Ltd. ("Thermo Fisher")
the world leader in serving science and supplier of analytical
instruments, life sciences solutions, specialty diagnostics,
laboratory, pharmaceutical and biotechnology services.
The collaboration agreement will enable EDX Medical and Thermo
Fisher to jointly develop and potentially commercialise a number of
proprietary qPCR assays - including novel and innovative cancer
diagnostic solutions. The multi project collaboration will harness
Thermo Fisher's powerful technologies and information translation
systems to deliver a number of advanced testing solutions in
development at EDX or licensed from partners, including a
proprietary assay to enable personalised radiotherapy and a novel
chemotherapy toxicity assay focusing on serious adverse events.
About Thermo Fisher Scientific
Thermo Fisher Scientific EMEA Ltd is part of Thermo Fisher
Scientific Inc. (NYSE: TMO) which is the world leader in serving
science, with annual revenue over $40 billion. Our Mission is to
enable our customers to make the world healthier, cleaner and
safer. Whether our customers are accelerating life sciences
research, solving complex analytical challenges, increasing
productivity in their laboratories, improving patient health
through diagnostics or the development and manufacture of
life-changing therapies, we are here to support them. Our global
team delivers an unrivaled combination of innovative technologies,
purchasing convenience and pharmaceutical services through our
industry-leading brands, including Thermo Scientific, Applied
Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services,
Patheon and PPD.
About EDX Medical Group
EDX Medical Group plc develops innovative digital diagnostic
products and services, enabling cost effective and timely delivery
of personalised treatment for cancer, heart disease and infectious
diseases. The company is listed on the AQSE Growth Market (TIDM:
EDX).
EDX Medical was founded by Professor Sir Chris Evans, OBE, a
very successful medical and life sciences entrepreneur with more
than 35 years of experience building innovative life sciences
companies.
By translating clinical insights into pragmatic solutions
combining advanced biological and digital technologies, EDX Medical
seeks to cost-effectively improve the detection and
characterisation of disease in order to select personal treatment
in a timely fashion.
Early disease detection and biologically-based personal
treatment is considered to be the most impactful way of reducing
deaths and lowering the cost of healthcare globally.
EDX Medical has established expertise in the design,
development, validation and sourcing of diagnostic testing
solutions to ISO 13485 and key laboratory tests performed by the
Company have been accredited to ISO 15189 by the United Kingdom
Accreditation Service (UKAS).
EDX Medical Group operates a molecular diagnostics and genomics
laboratory in Cambridge, UK, a Point of Care test development group
in Oxford (Hutano Diagnostics Ltd) and Torax Biosciences Ltd in
Ireland.
Learn more: www.edxmedical.co.uk
Contacts:
EDX Medical plc
Dr Mike Hudson (Chief Executive Officer) +44 (0)7812 345 301
Oberon Capital
Nick Lovering (Corporate Adviser)
Adam Pollock (Corporate Broking)
Mike Seabrook (Corporate Broking) +44 (0)20 3179 5300
Media House International
Ramsay Smith +44 (0)7788 414856
ramsay@mediahouse.co.uk
Gary McQueen + 44 (0)7834 694609
gary@mediahouse.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXMZMZMMGLGFZZ
(END) Dow Jones Newswires
November 21, 2023 02:00 ET (07:00 GMT)
EDX Medical (AQSE:EDX)
Historical Stock Chart
From May 2024 to Jun 2024
EDX Medical (AQSE:EDX)
Historical Stock Chart
From Jun 2023 to Jun 2024